Regencell Bioscience Holdings Ltd RGC

Regencell Bioscience: Changing the Way Patients are Treated

[sungrin1309]

Regencell Bioscience is a Hong Kong-based company that is focused on the research, development, and commercialization of Traditional Chinese Medicine (TCM) for the treatment of neurocognitive disorders and degenerations. The company, led by its Chairman and CEO, Yat-Gai Au, has a clear vision to help people improve their lives through the use of TCM.

Regencell has become a leader in the field, spearheading the efforts to alleviate the unmet medical needs of millions of people around the world. Through their research and development programs, the company is working to develop treatments for ADHD and ASD patients, as well as for infectious diseases that affect the human immune systems.

Recently, the company has been gaining attention for its clinical trials, specifically the EARTH Trial, which has shown that RGC-COV19TM is an effective formula for the alleviation and elimination of COVID-19 symptoms within 6 days. This not only helps to reduce the symptoms for patients, but also reduces the risk of hospitalizations and death. These results have shown the effectiveness of TCM and alternative medicine in a hyper-modern and tech-driven world.

Yat-Gai Au believes that it is crucial to have the right team in place in order to remain true to the company's values and continue to head in the right direction. The Regencell team is dedicated to ensuring that their services and products are effective, safe, and useful for their patients.

In addition to their commitment to TCM research and development, Regencell is also focused on the commercialization of their products. The company recently went public through an Initial Public Offering on the stock market, and since then, the company's shares have grown by approximately 247.31%.

Despite turbulent market conditions, Regencell is comfortably poised for growth. Yat-Gai Au and the majority of shareholders are insider investors, and have recently invested more than $5.9 million in the company, showing their confidence in the future of Regencell Bioscience

https://www.ibtimes.com/regencell-ceo-shares-his-vision-insights-aims-change-way-patients-are-treated-3600337